$ABMD (ABIOMED, Inc.)

$ABMD {{ '2016-09-27T13:10:21+0000' | timeago}} • Announcement

$ABMD said its Impella 2.5 and Impella 5.0 heart pumps received Pharmaceuticals and Medical Devices Agency approval from the Japanese Ministry of Health, Labor & Welfare (MHLW) for the treatment of drug-resistant acute heart failure.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$ABMD {{ '2017-06-30T13:07:57+0000' | timeago}} • Announcement

$ABMD said a study on hemodynamic support with its Impella heart pump yielded positive results. The study showed initiation of the heart pump prior to percutaneous coronary intervention on ‘unprotected left main coronary artery culprit lesion’ brought significant survival benefit to patients supported for cardiogenic shock following heart attack.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$ABT {{ '2017-06-16T10:42:39+0000' | timeago}} • Announcement

$ABT announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific.

$GE {{ '2017-06-14T12:04:29+0000' | timeago}} • Announcement

$GE's GE Additive and $SYK have entered a partnership agreement to support $SYK's growth in additive manufacturing. The agreement covers new additive machines, materials and services for $SYK's global supply chain operations.

$LLY {{ '2017-06-14T08:45:38+0000' | timeago}} • Announcement

Pharma firms $LLY and $INCY will present data from studies conducted on Olumiant, indicated for inflammatory and autoimmune diseases, at the Annual European Congress of Rheumatology being held in Madrid from June 14 to 17, 2017. Six abstracts evaluating Taltz, indicated for the treatment of psoriatic arthritis, will also be presented at the meet.

$BDX {{ '2017-06-12T07:19:32+0000' | timeago}} • Announcement

$BDX and $BCR received a request for additional information from the Federal Trade Commission in connection with BD's pending acquisition of C.R. Bard. In April 2017, BD agreed to buy Bard in a $24Bil transaction. Both companies expect to get regulatory approvals and close the transaction in the fall of 2017.

$ABT {{ '2017-06-09T14:38:24+0000' | timeago}} • Announcement

The Board of $ABT declared a quarterly common dividend of 26.5 cents per share. The dividend is payable Aug. 15, 2017, to shareholders of record as on July 14, 2017.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
ABMD (ABIOMED, Inc.)
Thursday, May 4 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
LMAT (LeMaitre Vascular, Inc.)
Wednesday, April 26 2017 - 9:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
NURO (NeuroMetrix Inc.)
Thursday, April 20 2017 - 12:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, March 14 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Monday, March 6 2017 - 10:00pm

AlphaGraphics you may like